PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
6 hedge funds and large institutions have $130K invested in PDL BioPharma, Inc. in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
392% more capital invested
Capital invested by funds: $26.5K → $130K (+$104K)
50% more funds holding
Funds holding: 4 → 6 (+2)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ATC
Argent Trust Co
Nashville,
Tennessee
|
+$102K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.51K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ATC
1
Argent Trust Co
Nashville,
Tennessee
| $102K | +$102K | +41,405 | New |
|
|
DT
2
Diversified Trust
Memphis,
Tennessee
| $26.5K | – | – | – |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $1.51K | +$1.51K | +612 | New |
|
PDLI Hedge Fund Activity: Q2 2023 in Review
6 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2023, worth a combined $130K — up 392% from $26.5K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PDLI positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Argent Trust Co, opening a new position worth an estimated $102K.
- 6 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2023, up from 4 in Q1 2023.
- Funds reported $130K of PDL BioPharma, Inc. stock for Q2 2023, up 392% quarter-over-quarter.
- 2 funds opened new PDL BioPharma, Inc. positions in Q2 2023 and 0 closed out, a net change of +2 holders.
- The largest PDL BioPharma, Inc. buyer in Q2 2023 was Argent Trust Co, an estimated $102K added.
Based on aggregated 13F filings for Q2 2023.